Positive News SentimentPositive NewsNASDAQ:HRTX Heron Therapeutics (HRTX) Stock Price, News & Analysis $1.34 +0.02 (+1.14%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Heron Therapeutics Stock (NASDAQ:HRTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Heron Therapeutics alerts:Sign Up Key Stats Today's Range$1.30▼$1.3550-Day Range$1.28▼$2.2352-Week Range$1.04▼$2.68Volume113,111 shsAverage Volume1.68 million shsMarket Capitalization$204.64 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingHold Company Overview Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. Read More Heron Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreHRTX MarketRank™: Heron Therapeutics scored higher than 87% of companies evaluated by MarketBeat, and ranked 179th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingHeron Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageHeron Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Heron Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Heron Therapeutics are expected to grow in the coming year, from ($0.13) to ($0.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Heron Therapeutics is -66.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Heron Therapeutics is -66.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Heron Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.68% of the outstanding shares of Heron Therapeutics have been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 20.3, which indicates bearish sentiment.Change versus previous monthShort interest in Heron Therapeutics has recently decreased by 5.76%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHeron Therapeutics does not currently pay a dividend.Dividend GrowthHeron Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.96 Percentage of Shares Shorted21.68% of the outstanding shares of Heron Therapeutics have been sold short.Short Interest Ratio / Days to CoverHeron Therapeutics has a short interest ratio ("days to cover") of 20.3, which indicates bearish sentiment.Change versus previous monthShort interest in Heron Therapeutics has recently decreased by 5.76%, indicating that investor sentiment is improving significantly. News and Social Media3.7 / 5News SentimentN/A News SentimentHeron Therapeutics has a news sentiment score of 1.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Heron Therapeutics this week, compared to 3 articles on an average week.Search Interest6 people have searched for HRTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows5 people have added Heron Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Heron Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $6,230,656.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 5.86% of the stock of Heron Therapeutics is held by insiders.Percentage Held by Institutions80.01% of the stock of Heron Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Heron Therapeutics' insider trading history. Receive HRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Heron Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HRTX Stock News HeadlinesHeron Therapeutics, Inc. (NASDAQ:HRTX) Director Buys $2,649,819.00 in StockAugust 13, 2025 | insidertrades.comHeron Therapeutics Signs New Headquarters LeaseAugust 28, 2025 | tipranks.comBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century.September 3 at 2:00 AM | Banyan Hill Publishing (Ad)Heron Therapeutics: The View From 30,000 Feet Amid The Zynrelef LaunchAugust 25, 2025 | seekingalpha.comHeron Therapeutics adopts tax benefits preservation planAugust 16, 2025 | msn.comHeron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder ValueAugust 15, 2025 | prnewswire.comHeron Therapeutics Signs Agreement with PatheonAugust 12, 2025 | msn.comHeron Therapeutics Announces Strategic Financial InitiativesAugust 12, 2025 | theglobeandmail.comSee More Headlines HRTX Stock Analysis - Frequently Asked Questions How have HRTX shares performed this year? Heron Therapeutics' stock was trading at $1.53 at the beginning of the year. Since then, HRTX stock has decreased by 12.7% and is now trading at $1.3350. How were Heron Therapeutics' earnings last quarter? Heron Therapeutics, Inc. (NASDAQ:HRTX) released its earnings results on Friday, August, 8th. The biotechnology company reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of ($0.01) by $0.01. The biotechnology company earned $37.20 million during the quarter, compared to analyst estimates of $38.08 million. Read the conference call transcript. Does Heron Therapeutics have any subsidiaries? Heron Therapeutics subsidiaries include Heron Therapeutics B.V.. Who are Heron Therapeutics' major shareholders? Heron Therapeutics' top institutional shareholders include Palisade Capital Management LP (3.32%), Tejara Capital Ltd (2.95%), Geode Capital Management LLC (2.34%) and AIGH Capital Management LLC (1.97%). Insiders that own company stock include Rubric Capital Management Lp, Adam Morgan, Craig A Collard, Ira Duarte and William P Forbes. View institutional ownership trends. How do I buy shares of Heron Therapeutics? Shares of HRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Heron Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Heron Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings8/08/2025Today9/03/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRTX CIK818033 Webwww.herontx.com Phone(858) 251-4400Fax650-365-6490Employees300Year Founded1983Price Target and Rating Average Price Target for Heron Therapeutics$4.50 High Price Target$6.00 Low Price Target$3.00 Potential Upside/Downside+240.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.58 million Net Margins-0.62% Pretax Margin-0.62% Return on EquityN/A Return on Assets-0.40% Debt Debt-to-Equity RatioN/A Current Ratio0.82 Quick Ratio0.53 Sales & Book Value Annual Sales$144.29 million Price / Sales1.40 Cash FlowN/A Price / Cash FlowN/A Book Value($0.18) per share Price / Book-7.33Miscellaneous Outstanding Shares153,290,000Free Float144,309,000Market Cap$202.34 million OptionableOptionable Beta1.22 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:HRTX) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Heron Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Heron Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.